An American federal trade regulator has imposed conditions on Sun Pharmaceuticals’ acquisition of Ranbaxy on the grounds that the USD 4 billion proposed deal would likely be anti-competitive.
US regulator imposes conditions on Sun's Ranbaxy acquisition
No comments:
Post a Comment